NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test of new pill targets 'Undruggable' cancer mutation
Disease control TerminatedThis early-stage study tested a new oral drug, AZD0022, alone and combined with another cancer drug, in people with advanced solid tumors driven by a specific genetic change called KRASG12D. The main goals were to find a safe dose and see if the treatment caused any side effects.…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Double-Duty drugs: testing a Two-Pronged attack on lung cancer before and after surgery
Disease control TerminatedThis study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab), given with or without standard chemotherapy, for people with certain stages of non-small cell lung cancer that could be removed by surgery. The goal was to see if giving these drugs both be…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New immune therapy tested for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called TAK-186 in adults with advanced cancers of the head & neck, lung, or colon that could not be removed by surgery. The main goal was to find a safe dose and understand the drug's side effects. Researchers also looked for early signs t…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC